Clinical trial
Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer
NCT00109811 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00109811 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer |
| Official title | A Phase 2 Study of Prostate Specific Antigen Peptide 3A (PSA: 154-163(155L) ) (NSC # 722932, IND#9787) With Montanide ISA-51(NSC #675756, IND #9787) or Montanide® ISA 51 VG (NSC 737063) Vaccination in Prostate Cancer Recurrent |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Prostate, Recurrent Prostate Cancer |
| Intervention type | Biological, Other |
| Interventions | PSA:154-163(155L) peptide vaccine, incomplete Freund's adjuvant, laboratory biomarker analysis |
| Enrollment | 32 |
| Start date | Mar 1, 2005 |
| Primary completion | Sep 1, 2007 |
| First posted | May 4, 2005 |
| Last update posted | Jan 23, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: